Abstract
Drug studies in developing pediatric patients, especially newborns, create many ethical challenges that can be analyzed in terms of respect for persons, justice, and beneficence/maleficence as outlined in the Belmont Report. This report describes some of the ethical challenges in conducting drug studies in pediatric patients that must be considered when planning studies and offers some solutions to meet those challenges. Methods of optimal study design should be utilized to limit the number of patients and the number of blood samples. Parental permission should be obtained with equipoise, although the parents of a sick newborn may feel an internal pressure for their child to participate in a study of a new and potentially superior therapy. If appropriate to the study, consent before labor and delivery when parents are less stressed is optimal. It may be difficult or impossible to know all the risks and benefits accompanying studies in newborns due to the limited number of randomized controlled studies in this population. Many more carefully designed, randomized controlled studies of drugs are needed to address the therapeutic needs of the developing pediatric population. For sick newborns cared for in the neonatal intensive care unit (NICU), those studies should be better focused on the drugs used daily in their cares.
Similar content being viewed by others
References
Food and Drug Administration Modernization Act of 1997. (Public Law 105–115); 1997. Available from: http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDAMA/FullTextofFDAMAlaw/default.htm. Accessed 27 July 2014.
US Food and Drug Administration Safety and Innovation Act. (Public Law 112–144); 2012. Available from: http://www.gpo.gov/fdsys/pkg/PLAW-112publ144/pdf/PLAW-112publ144.pdf. Accessed 27 July 2014.
The European Parliament and the Council of the European Union. Paediatric Regulation (EC No 1901/2006). 2006. http://ec.europa.eu/health/human-use/paediatric-medicines/index_en.htm. Accessed 10 Oct 2014.
US Food and Drug Administration Pediatric Exclusivity Statistics. Last update July 28, 2014. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm050006.htm. Accessed 29 July 2014.
US Food and Drug Administration New Pediatric Labeling Information Database. Last update July 28, 2014. Available from: http://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=labelingdatabase. Accessed 28 July 2014.
Laughon MM, Avant D, Tripathi N, Hornik CP, Cohen-Wolkowiez M, Clark RH, et al. Drug labeling and exposure in neonates. JAMA Pediatr. 2014;168(2):130–6.
American Academy of Pediatrics Committee on Drugs. Uses of drugs not described in the package insert (off-label uses). Pediatrics. 2002;110(1 Pt 1):181–3.
Lebacqz K. Pediatric drug investigation: current ethical guidelines. In: Mirkin BL, editor. Clinical pharmacology and therapeutics, a pediatric perspective. Chicago: Year Book Medical Publishers, Inc.; 1978. p. 279–97.
Belmont Report: Ethical principles and guidelines for the protection of human subjects of research. Report of the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. 1979. Available from: http://www.hhs.gov/ohrp/humansubjects/guidance/belmont.html. Accessed 24 July 2014.
Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Committee on Drugs, American Academy of Pediatrics. Pediatrics. 1995;95(2):286–94.
Shaddy RE, Denne SC, Committee on Drugs and Committee on Pediatric Research. Clinical report—guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics. 2010;125(4):850–60.
Roth-Cline MD, Nelson RM. Ethical considerations in conducting pediatric research. In: Mulberg AE, Murphy D, Dunne J, Mathis LL, editors. Pediatric drug development, concepts and applications. Hoboken: Wiley; 2013. p. 83–97.
Simar MR. The consent and assent process in pediatric clinical trials. In: Mulberg AE, Murphy D, Dunne J, Mathis LL, editors. Pediatic drug development, concepts and applications. Hoboken: Wiley; 2013. p. 94–104.
The Spinal Muscular Atrophy Drug Development Pipeline. 2014 ‘Last Update’ January 22, 2014. Available from: http://www.fsma.org/Research/DrugPipeline/. Accessed 27 July 2014.
Burns LE, Hodgeman JE, Cass AB. Fatal and circulatory collapse in premature infants receiving chloramphenicol. N Engl J Med. 1959;261(26):1318–21.
International Congress on Harmonization: Clinical Investigation of Medicinal Products in the Paediatric Population. ICH E11. Last update 2001. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002926.pdf. Accessed 28 July 2014.
Mulberg AE, Murphy D, Dunne J, Mathis LL, editors. Pediatric drug development. Concepts and application. 2nd ed. Hoboken: Wiley; 2013.
US Food and Drug Administration Guidance for Industry Pediatric Study Plans: Content of and Process for Submitting Initial Pediatric Study Plans and Amended Pediatric Study Plans In: Services USDoHaH (ed). Washington, DC: 2013. p. 1–16.
Carlo WA, Finer NN, Walsh MC, Rich W, Gantz MG, Laptook AR, et al. Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med. 2010;362(21):1959–69.
Resnik DB. What are reasonably foreseeable risks? Am J Bioeth. 2013;13(12):29–30.
Wilfond BS, Magnus D, Antommaria AH, Appelbaum P, Aschner J, Barrington KJ, et al. The OHRP and SUPPORT. N Engl J Med. 2013;368(25):e36.
Drazen JM, Solomon CG, Greene MF. Informed consent and SUPPORT. N Engl J Med. 2013;368(20):1929–31.
Hudson KL, Guttmacher AE, Collins FS. In support of SUPPORT—a view from the NIH. N Engl J Med. 2013;368(25):2349–51.
Tarnow-Mordi WO, Darlow B, Doyle L. Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med. 2010;363(13):1285 (author reply -6).
Rocchi F, Tomasi P. The development of medicines for children. Part of a series on pediatric pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni. Pharmacol Res. 2011;64(3):169–75.
Marsot A, Boulamery A, Bruguerolle B, Simon N. Population pharmacokinetic analysis during the first 2 years of life: an overview. Clin Pharmacokinet. 2012;51(12):787–98.
Millership JS. Microassay of drugs and modern measurement techniques. Paediatr Anaesth. 2011;21(3):197–205.
Alleman BW, Bell EF, Li L, Dagle JM, Smith PB, Ambalavanan N, et al. Individual and center-level factors affecting mortality among extremely low birth weight infants. Pediatrics. 2013;132(1):e175–84.
Allen MC, Donohue PK, Dusman AE. The limit of viability–neonatal outcome of infants born at 22–25 weeks’ gestation. N Engl J Med. 1993;329(22):1597–601.
Schlapbach LJ, Adams M, Proietti E, Aebischer M, Grunt S, Borradori-Tolsa C, et al. Outcome at two years of age in a Swiss national cohort of extremely preterm infants born between 2000 and 2008. BMC Pediatr. 2012;12:198.
Office for Health Research Protection (OHRP)—Categories of Research. Categories of research that may be reviewed by the Institutional Review Board (IRB) through an expedited review procedure. Categories of Research (2)(b). Last update 1998. Available from: http://www.hhs.gov/ohrp/policy/expedited98.html. Accessed 29 July 2014.
Smith PB, Cohen-Wolkowiez M, Castro LM, Poindexter B, Bidegain M, Weitkamp JH, et al. Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections. Pediatr Infect Dis J. 2011;30(10):844–9.
Wade KC, Wu D, Kaufman DA, Ward RM, Benjamin DK Jr, Sullivan JE, et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother. 2008;52(11):4043–9.
Ward RM, Drover DR, Hammer GB, Stemland CJ, Kern S, Tristani-Firouzi M, et al. The pharmacokinetics of methadone and its metabolites in neonates, infants, and children. Paediatr Anaesth. 2014;24(6):591–601.
Kimko HC, Duffull SB. Simulation for designing clinical trials: a pharmacokinetic–pharmacodynamic modeling perspective. New York: Marcel Dekker; 2003.
Acknowledgments
Neither Catherine Sherwin or Robert Ward have any potential conflicts of interest related to the contents of this paper. Both authors participated in the outline, writing, and review of this manuscript. No sources of funding were used to support the writing of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of the topical collection on Ethics of Pediatric Drug Research.
Rights and permissions
About this article
Cite this article
Ward, R.M., Sherwin, C.M.T. Ethics of Drug Studies in the Newborn. Pediatr Drugs 17, 37–42 (2015). https://doi.org/10.1007/s40272-014-0099-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40272-014-0099-8